Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

HI-FLASH Heavy Ion FLASH

Coordinator
Gsi Helmholtzzentrum Fur Schwerionenforschung GmbH, Germany
Runs
1 April 2026 to 31 March 2031
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101198395

What the project is doing

In the project's own words, from its summary on CORDIS.

Charged particle therapy is generally acknowledged as the most advanced type of radiotherapy (RT). Particle therapy patients are treated either with high-energy protons or 12C-ions, but there is a general agreement that heavier ions would be highly beneficial in treating extremely resistant, hypoxic and lethal tumors, such as glioblastoma (GBM). Unfortunately, the use of very heavy ions is constrained by their excessive normal tissue toxicity.

A way to enable very heavy ion therapy with acceptable toxicities is to make use of the recently discovered FLASH effect. This effect occurs when ultra-high dose-rate (UHDR) electrons or protons are used and results in significantly sparing the normal tissues whilst maintaining tumour control. Although the molecular mechanism is still unclear, the FLASH effect considerably broadens the therapeutic window and has proven to be a game-changer in radiotherapy.

While my group at GSI has pioneered the first demonstration of the FLASH effect with high-energy carbon ions, UHDR use of even heavier ions can be safe and very effective for very resistant tumor. GSI is the only facility world-wide where the FLASH effect can be explored with ions heavier than carbon. In fact, the GSI synchrotron can accelerate all ions for H to U up to very high energy and intensity, and my group has developed a unique technology to perform 3D conformal UHDR irradiation using 3D-printed range modulators.

We will perform UHDR irradiation experiments with 20Ne-ions using a GBM rat model and will compare survival, toxicity and tumour control with the same ion at conventional dose-rate and with UHDR protons as a reference. If successful, HI-FLASH will pave the way for the use of heavy ions in cancer treatment, improving outcomes for patients with highly resistant and lethal tumors like GBM.

Topics

Who is involved

OrganisationCityCountryRole
Gsi Helmholtzzentrum Fur Schwerionenforschung GmbHDarmstadtGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS